Data from ARTISTRY trials demonstrated that switching to a single-tablet regimen of bictegravir and lenacapavir is noninferior to continuing current antiretroviral therapy.
The newly approved oral formulation features a smaller pill size in 1.5mg, 4mg, and 9mg strengths while maintaining the efficacy and safety profile of the previous oral semaglutide version.
HealthDay News — Dietary and lifestyle modifications are reasonable first-line therapies for symptomatic hemorrhoids, according to a clinical practice update issued by the American Gastroenterological ...
Novo Nordisk submitted a BLA to the Food and Drug Administration for denecimig for the treatment of hemophilia A in September 2025.
The US Food and Drug Administration (FDA) is moving to speed drug development and review by launching real-time clinical trials. The move could soon mean more o ...
However, most patients report preferring LAI-ART administered monthly or once every 2 months vs daily oral ART.
Gene therapy approved to restore hereditary hearing loss; investigational treatment shows hair coverage improvements in male ...
Similar incidence of death, new renal-replacement therapy, persistent kidney dysfunction reported with balanced fluid and 0.9 ...
The research suggests that the increase is partly due to introduction of the HAART drug regimen, which transformed HIV from a terminal condition into a manageable chronic disease. HealthDay News — ...
Patients received either mailed FIT with automated text message outreach from study personnel or mailed FIT-DNA with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results